)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (REGN) investor relations material
Regeneron Pharmaceuticals Collaboration summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Collaboration summary1 Oct, 2026
Opening remarks and agenda
Expanded global alliance opens a new chapter in a 20-year collaboration focused on next-generation Type 2 medicines.
Prepared remarks covered partnership strategy, pipeline, deal terms and operations, followed by Q&A.
Objectives of the partnership
Extend the alliance beyond DUPIXENT and sustain leadership in Type 2 inflammatory diseases with differentiated, long-acting treatments.
Pursue longer dosing intervals without compromising efficacy or safety, addressing treatment burden and patient convenience.
Combine antibody discovery and development expertise with global development and commercial capabilities to accelerate access worldwide.
Partner introductions and roles
Four fully human, long-acting antibodies join the alliance: IL-13, IL-4/IL-13 bispecific, IL-4 receptor alpha and IL-4 antibodies.
Sanofi provides an option to add lunsekimig, an IL-13/TSLP Nanobody, at the alliance's discretion following COPD Phase III results.
Regeneron leads development decisions; Sanofi retains final commercial decisions, including access and pricing, with increased payer-engagement participation for Regeneron.
Sanofi's global development, commercial, supply, device and patient-support capabilities complement antibody discovery and joint immunology expertise.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Regeneron Pharmaceuticals
- Double-digit growth, pipeline milestones, and patient-focused innovation define the outlook.REGN
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - Strong growth in Dupixent and EYLEA HD, with new launches and pipeline assets driving future momentum.REGNMorgan Stanley 24th Annual Global Healthcare Conference
- Record sales, pipeline milestones, and strategic alliances drive robust growth outlook.REGNWells Fargo 21st Annual Healthcare Conference
- Q2 2026 revenue up 17% to $4.3B, with record Dupixent, EYLEA HD, and Libtayo sales; EPS up 11%.REGNQ2 2026
- Strong product growth and a rich pipeline position the company for continued expansion.REGNBarclays 28th Annual Global Healthcare Conference
- Earnings and pipeline momentum accelerate, with innovation and cash fueling future growth.REGNTD Cowen 46th Annual Health Care Conference
- Q4 2025 revenue rose 3% to $3.9B, driven by Dupixent, EYLEA HD, and Libtayo growth.REGNQ4 2025
- Factor XI antibodies cut VTE rates post-surgery with no major bleeding; broad Phase 3 underway.REGNInvestor Update
- Q3 2025 saw strong Dupixent and EYLEA HD growth, offsetting EYLEA declines amid market pressures.REGNQ3 2025
Next Regeneron Pharmaceuticals earnings date
Q3 202630 Oct, 2026
Regeneron Pharmaceuticals
Next Regeneron Pharmaceuticals earnings date
Q3 202630 Oct, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Regeneron Pharmaceuticals Inc is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company has a pipeline of product candidates comprising multiple therapeutic candidates in Phase I and Phase II clinical studies for the treatment of cancer, wet age-related macular degeneration and diabetic macular edema, atopic dermatitis, asthma, pain, and monoclonal antibodies.